Art

J-GLOBAL ID：201602281126664817   Reference number：16A1380473

Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction

トルバプタンは鬱血性心不全で駆出率を維持している患者および駆出率減少を伴う患者の長期予後を改善する

Author (2)： Imamura Teruhiko (Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo) ,  Kinugawa Koichiro (Second Department of Internal Medicine, University of Toyama)
Material： International Heart Journal  (Int Heart J)
Volume： 57  Issue： 5  Page： 600-606(J-STAGE)  Publication year： 2016 
JST Material Number： Z0752A  ISSN： 1349-2365  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： Readmission rate

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A1380473&from=J-GLOBAL&jstjournalNo=Z0752A") }}

Author keywords (4)： Vasopressin ,  HFpEF ,  Aquaporin ,  Chronic kidney disease

JST classification (1)： Drug therapy(=pharmacotherapy)for cardiovascular system diseases  (GJ05020M)

Substance index (2)： Arginine Vasopressin ,  OPC-41061

Reference (29)：

• 1. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.
• 2. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273-8.
• 3. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.
• 4. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-43.
• 5. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev 2007; 25: 1-13. (Review)

Terms in the title (5)： トルバプタン ,  鬱血性心不全 ,  駆出率 ,  患者 ,  長期予後